Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine vs Magnesium Sulphate as Adjuvant to Lidocaine in Peribulbar Block for DCR
NCT07675616Recruiting
- Sponsor
- Cairo University
- Start
- May 2026
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Randomised trial of dexmedetomidine and magnesium sulfate in nasolacrimal duct obstruction (NLDO) (3 arms), sponsored by Cairo University. Primary endpoint: Change in mean arterial blood pressure at 2 hours. Started May 2026; status: recruiting.
02
Drugs
dexmedetomidinemagnesium sulfate
03
Conditions
nasolacrimal duct obstruction (NLDO)
Beyond the preview
Go deeper on NCT07675616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07675616.